104162 Federal Register / Vol. 89, No. 245 / Friday, December 20, 2024 / Notices 

Jeffrey M. Zirger, 

Lead, Information Collection Review Office, 

Office of Public Health Ethics and 

Regulations, Office of Science, Centers for 

Disease Control and Prevention. 

[FR Doc. 2024–30480 Filed 12–19–24; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Safety and Occupational Health Study 

Section; Notice of Solicitation of 

Nominations for Appointment; 

Correction 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice; correction. 

SUMMARY: In accordance with the 

Federal Advisory Committee Act, the 

Centers for Disease Control and 

Prevention (CDC), within the 

Department of Health and Human 

Services (HHS), is seeking nominations 

for membership on the Safety and 

Occupational Health Study Section 

(SOHSS). SOHSS consists of 20 experts 

in fields associated with occupational 

medicine and nursing, industrial 

hygiene, occupational safety and 

engineering, toxicology, chemistry, 

safety and health education, 

ergonomics, epidemiology, economic 

science, psychology, pulmonary 

pathology/physiology, and social 

science. 

DATES: Nominations for membership on 

SOHSS must be received no later than 

January 31, 2025. Packages received 

after this time will not be considered for 

the current membership cycle. 

ADDRESSES: All nominations should be 

mailed to Dr. Michael Goldcamp, 1095 

Willowdale Road, Morgantown, West 

Virginia 26505 or emailed to 

MGoldcamp@cdc.gov. 

FOR FURTHER INFORMATION CONTACT: 

Michael Goldcamp, Ph.D., Scientific 

Review Officer, Office of Extramural 

Programs, National Institute for 

Occupational Safety and Health, Centers 

for Disease Control and Prevention, 

1095 Willowdale Road, Morgantown, 

West Virginia 26505. Telephone: (304) 

285–5951; email: MGoldcamp@cdc.gov. 

SUPPLEMENTARY INFORMATION: 

Correction 

Notice is hereby given of a correction 

in the SUPPLEMENTARY INFORMATION

section of the original solicitation of 

nominations notice, which was 

published in the Federal Register on 

December 2, 2024, 89 FR 95214. 

The notice is being amended to 

remove the sentence concerning Special 

Government Employees, since members 

of the Safety and Occupational Health 

Study Section serve as Peer Review 

Consultants. The SUPPLEMENTARY

INFORMATION section should read as 

follows: 

SUPPLEMENTARY INFORMATION: 

Nominations are sought for individuals 

who have the expertise and 

qualifications necessary to contribute to 

the accomplishment of the objectives of 

the Safety and Occupational Health 

Study Section (SOHSS). Nominees will 

be selected based on expertise in the 

fields of occupational medicine and 

nursing, industrial hygiene, 

occupational safety and engineering, 

toxicology, chemistry, safety and health 

education, ergonomics, epidemiology, 

economic science, psychology, 

pulmonary pathology/physiology, and 

social science. Members may be invited 

to serve up to four-year terms. Selection 

of members is based on candidates’ 

qualifications to contribute to the 

accomplishment of SOHSS objectives 

(https://www.cdc.gov/faca/committees/ 

sohss.html). 

Department of Health and Human 

Services (HHS) policy stipulates that 

committee membership be balanced in 

terms of points of view represented and 

the committee’s function. Appointments 

shall be made without discrimination 

on the basis of age, race, ethnicity, 

gender, sexual orientation, gender 

identity, HIV status, disability, and 

cultural, religious, or socioeconomic 

status. Nominees must be U.S. citizens 

and cannot be full-time employees of 

the U.S. Government. Current 

participation on Federal workgroups or 

prior experience serving on a Federal 

advisory committee does not disqualify 

a candidate; however, HHS policy is to 

avoid excessive individual service on 

advisory committees and multiple 

committee memberships. The Centers 

for Disease Control and Prevention 

(CDC) reviews potential candidates for 

SOHSS membership each year and 

provides a slate of nominees for 

consideration to the Secretary of HHS 

for final selection. HHS notifies selected 

candidates of their appointment near 

the start of the term in October 2025, or 

as soon as the HHS selection process is 

completed. Note that the need for 

different expertise varies from year to 

year and a candidate who is not selected 

in one year may be reconsidered in a 

subsequent year. 

Candidates should submit the 

following items: 

D Current curriculum vitae, including 

complete contact information 

(telephone numbers, mailing address, 

email address). 

D At least one letter of 

recommendation from person(s) not 

employed by HHS. Candidates may 

submit letter(s) from current HHS 

employees if they wish, but at least one 

letter must be submitted by a person not 

employed by an HHS agency (e.g., CDC, 

National Institutes of Health, Food and 

Drug Administration). 

Nominations may be submitted by the 

candidate or by the person/organization 

recommending the candidate. 

The Director, Office of Strategic 

Business Initiatives, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Office of Strategic Business 

Initiatives, Office of the Chief Operating 

Officer, Centers for Disease Control and 

Prevention. 

[FR Doc. 2024–30410 Filed 12–19–24; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Notice of Award of a Sole Source 

Cooperative Agreement to Fund 

Secretaria Ejecutiva del Consejo de 

Ministros de Salud de Centroamerica y 

Republica Dominicana (SE–COMISCA) 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC), located 

within the Department of Health and 

Human Services (HHS), announces the 

award of approximately $5,000,000, 

with an expected total funding of 

approximately $25,000,000 over a 5-year 

period, to SE–COMISCA. The award 

will build upon previous efforts by the 

CDC in collaboration with Ministries of 

Health of Central America and the 

Dominican Republic (SE–COMISCA). 

DATES: The period for this award will be 

September 30, 2025 through September 

29, 2030. 


ddrumheller on DSK120RN23PROD with NOTICES1
Federal Register / Vol. 89, No. 245 / Friday, December 20, 2024 / Notices 104163 

FOR FURTHER INFORMATION CONTACT: 

Broderick Yoerg, Division of Global 

Health Protection, Global Health Center, 

Centers for Disease Control and 

Prevention, 1600 Clifton Rd., Atlanta, 

GA 30329, email: DGHPNOFOs@

cdc.gov, telephone: 404–234–0666. 

SUPPLEMENTARY INFORMATION: The sole 

source award will target increased 

capacity at the national and subnational 

level to implement and achieve 

outbreak/epidemic/pandemic control in 

line with US Government (USG) and 

CDC strategy. This collaborative effort 

has led to significant progress in various 

areas under the Global Health Strategic 

Framework, including One Health 

workshops in multiple countries to 

prioritize zoonotic diseases and the 

development of a joint action plan for 

Central America. 

SE–COMISCA is the only entity that 

can carry out this work, as it will 

improve outbreak control capacity, 

better integration between health 

systems, and increased equity in 

healthcare access for all populations, 

especially those historically 

marginalized. 

Summary of the Award 

Recipient: SE–COMISCA 

Purpose of the Award: The purpose of 

this award is to support Global Health 

Security goals in Central America and 

the Dominican Republic by 

collaborating with MOH and other 

partners. Efforts will focus on reaching 

underserved populations, prioritizing 

equity to build resilient health systems 

that protect vulnerable groups. 

Amount of Award: $5,000,000 in 

Federal Fiscal Year (FFY) 2025 funds, 

with a total estimated $25,000,000 for 

the 5-year period of performance, 

subject to availability of funds. 

Authority: This program is authorized 

under section 307 of the Public Health 

Service Act [42 U.S.C. 24l) and Section 

301(a)[42 U.S.C. 24l(a) of the Public 

Health Service Act. 

Period of Performance: September 30, 

2025 through September 29, 2030. 

Dated: December 10, 2024. 

Terrance Perry, 

Acting Director, Office of Grants Services, 

Centers for Disease Control and Prevention. 

[FR Doc. 2024–30223 Filed 12–19–24; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[Docket No. CDC–2020–0046; NIOSH–233– 

C] 

Hazardous Drugs: NIOSH List of 

Hazardous Drugs in Healthcare 

Settings, 2024 and Final Reevaluation 

Determinations for Liraglutide and 

Pertuzumab 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: General notice. 

SUMMARY: The National Institute for 

Occupational Safety and Health 

(NIOSH) of the Centers for Disease 

Control and Prevention (CDC), in the 

Department of Health and Human 

Services (HHS), announces the 

publication of the NIOSH List of 

Hazardous Drugs in Healthcare Settings, 

2024, as well as final reevaluation 

determinations removing the drugs 

liraglutide and pertuzumab from the 

NIOSH List of Hazardous Drugs in 

Healthcare Settings. 

DATES: The documents announced in 

this notice are available on December 

20, 2024. 

ADDRESSES: The documents announced 

in this notice are available in the docket 

at www.regulations.gov and through the 

NIOSH Hazardous Drug Exposures in 

Healthcare website at https://

www.cdc.gov/niosh/healthcare/ 

hazardous-drugs/index.html. 

FOR FURTHER INFORMATION CONTACT: 

Jerald Ovesen, NIOSH, Robert A. Taft 

Laboratories, 1090 Tusculum Avenue, 

MS–C15, Cincinnati, OH 45226, 

telephone: (513)533–8472 (not a toll-free 

number), email: jovesen@cdc.gov. 

SUPPLEMENTARY INFORMATION: This 

notice is organized as follows: 

I. Public Participation 

II. Background 

III. NIOSH Response to Public Comment in 

the May 2020 Federal Register Notice 

and Request for Comment 

A. General Characteristics of the List 

1. Timing of the List 

2. Drugs That Did Not Meet the NIOSH 

Hazardous Drug Criteria 

B. General Drug Descriptors 

1. Unique Identifiers 

2. Use of AHFS Classifications 

3. Use of AHFS Code for Hormone Drug 

Classification 

4. Monoclonal Antibodies as a Class of 

Drugs 

5. Progestins 

6. Additional Information Requested 

C. General Reorganization of the List 

1. Content of Tables 

2. DailyMed and DrugBank Links 

D. Drugs Not on the Draft 2020 List 

1. Drugs Proposed in February 2018 and 

Not Added to the Draft 2020 List 

2. Bacillus Calmette-Guerin (BCG) 

3. Botulinum Toxins 

E. Requests for Specific Drugs To Be 

Removed From the List 

1. Blinatumomab 

2. Carfilzomib 

3. Eslicarbazepine, Lomitapide, 

Mifepristone 

4. Hazardous Drugs Listed for 

Reproductive and Developmental Effects: 

Cabergoline, Clonazepam, Fluconazole, 

Plerixafor, Riociguat, and Ziprasidone 

5. Icatibant 

6. Leuprolide 

7. Olaparib and Teriflunomide 

8. Oxytocin and Other Oxytocic Drugs 

9. Paroxetine 

10. Spironolactone 

11. Topiramate 

12. Ulipristal 

13. Vigabatrin 

F. Placement of Specific Drugs Within the 

List 

1. Carfilzomib 

2. Dasatinib and Imatinib 

3. Eribulin 

4. Exenatide 

5. Ganciclovir and Valganciclovir 

6. Hormonal Agents: Goserelin, Degarelix, 

Leuprolide, Estrogens, and Progesterone 

7. Mycophenolate Mofetil and 

Mycophenolic Acid 

8. Sirolimus and Other Related mTOR 

Targeting Drugs 

9. Thalidomide, Lenalidomide, and 

Pomalidomide 

10. Vandetanib 

G. Specific Drugs Classification/ 

Identification 

1. Triptorelin 

2. Ziv-Aflibercept, Ado-Trastuzumab 

Emtansine, Fam-Trastuzumab 

Deruxtecan 

H. Suggested Copyedits 

IV. NIOSH Response to Public Comment and 

Peer Review in the January 2024 Federal 

Register Notice and Request for 

Comment on Proposed Removal of 

Liraglutide and Pertuzumab From the 

List 

A. Public Comment 

1. General Comments 

2. Liraglutide 

3. Pertuzumab 

a. Is this an appropriate method for 

evaluating the potential for exposure to 

pertuzumab? 

b. Is oligohydramnios the best health effect 

to evaluate? If not, what other health 

effect(s) should be evaluated and why? 

c. Is a needlestick injury the only 

reasonable route of exposure for 

healthcare workers? 

d. Are the assumptions about the amount 

of exposure to pertuzumab in a 

healthcare setting reasonable? 

i. Inhalation 

ii. Percutaneous Exposure 

iii. Oral exposure 

e. What alternatives could be considered to 

this approach for monoclonal antibodies 

to characterize the potential hazard to 

workers? 


ddrumheller on DSK120RN23PROD with NOTICES1